The brachytherapy industry is primarily driven by the rising incidence of prostate cancer occurrences. According to the American Cancer Society, around 161,370 people in the United States were diagnosed with prostate cancer in 2017, with approximately 26,730 deaths related to prostate cancer. In the United States, prostate cancer is the third greatest cause of death among males. The expanding acceptance of high dose rate brachytherapy and the rising prevalence of obesity are two key reasons driving the brachytherapy industry forward. However, radiation therapy side effects such as hair loss, fatigue, appetite loss, and nausea are likely to stifle the brachytherapy market's expansion.
Click here for Brachytherapy Market Report: